

# Overview of HPV related disease incidence, mortality, social and economic impact in Sri Lanka



Present by: Dr. Suraj Perera National Cancer ControlProgramme Ministry of Health, Sri Lanka



Ministry of Health

South Asia Regional Meeting

HPV Prevention and Control Landscape and the way forward.

 $13^{h}$  ,  $14^{h}$  and  $15^{h}$  - Dec 2022– New Delhi, India.

# Overview of HPV related disease incidence, mortality, social and economic impact in Sri Lanka

- Burden of Cancer in Sri Lanka
- Burden of HPV related cancers Incidence & mortality with special emphasis for cervical cancer
- Other evidence of HPV burden in Sri Lanka
- Social & Economic impact









## Estimated Mid Year Population (2021) Total - 22,155,748


Male - 10,727,141 Female 11,428,607

Indicator		Year	Data	Source
Health and Nutriti	on Indicators			
Life expectancy at birth (years)	Female Male	2011- 2013	78.6	Department of Census and Statistics (Life Tables for Sri Lanka 2011-2013 by District and Sex)
Neonatal mortality r	ate (per 1,000 live births)	2015*	6.0	Registrar General's Department
Infant mortality rate	nfant mortality rate (per 1,000 live births)		8.5	
Under-five mortality	rate (per 1,000 live births)	2015*	10.1	
Average No. of child	verage No. of children born to ever married women in Sri Lanka		2.4	Census of Population & Housing, 2012
Maternal mortality r	aternal mortality ratio (per 100,000 live births)		25.7	Registrar General's Department
Low-birth-weight rat	w-birth-weight rate per 100 live births in government hospitals		16.0	Medical Statistics Unit




#### **Evolving Model of Cancer Registration System in Sri Lanka**





# www.nccp.health.gov.lk

# Number of newly detected cancers (Male, Female, Total) in Sri Lanka 2020519



# Age Standardized Incidence Rates (2005 - 2019) - Both



# No. of HPV related cancers detected among males in Sri Lanka 2022019

Site of Cancer	2012	2013	2014	2015	2016	2017	2018	2019
Tonsil (C09)	213	168	182	254	228	221	152	116
Other oropharynx ( C10)	124	109	132	129	145	136	150	165
Anus (C21)	34	35	60	64	71	74	79	93
Penis (C60)	87	98	97	110	172	121	145	151





COALITION to STRENGTHEN the **HPV IMMUNIZATION** COMMUNITY



# Age Standardized Incidence Rate of HPV Related Cancers among males in Sri Lanka-2019



# No. of HPV related cancers detected among females in Sri Lanka 2022019

Site of Cancer	2012	2013	2014	2015	2016	2017	2018	2019
Tonsil (C09)	19	16	14	30	29	35	17	17
Other oropharynx ( C10)	11	14	16	11	33	12	14	24
Anus (C21)	28	37	39	39	57	49	74	63
Vulva (C51)	37	22	44	56	62	54	61	48
Vagina (C52)	36	45	62	51	54	57	83	59
Cervix (C53)	905	895	1090	1008	1246	1071	1073	1114







COALITION to STRENGTHEN the HPV IMMUNIZATION COMMUNITY



# Age Standardized Incidence Rate of HPV Related Cancers among Females in Sri Lanka-2012 (Except cervical cancer)




# Crude & Age Standardized Incidence Rate of Cervical Cancer in Sri Lanka 2020519



THE INCLEN TRUST INTERNATIONAL

## Age Specific Incidence Rate of Cervical Cancer in Sri Lanka 2020619










# Most common cancers among femalein Sri Lanka 2019



# Mortality due to Cancers in Sri Lanka 2015

13,825	7,726	6,099
1,022	799	223
641	379	262
475	279	196
375	204	171
791	528	263
137	71	66
231	166	65
1,155	847	308
2	2	-
668	16	652
144	-	<mark>144</mark>
312	-	312
220	-	220
223	223	-
160	141	19
517	295	222
276	176	100
157	96	61
589	317	272
5,622	3,131	2,491
108	56	52
	1,022 641 475 375 791 137 231 1,155 22 668 668 144 312 220 223 223 160 517 276 157 589 589 5,622	1,022 799   641 379   475 279   375 204   791 528   137 71   231 166   1,155 847   2 2   668 16   144 -   212 2   668 16   144 -   220 -   223 223   160 141   517 295   276 176   157 96   589 317   5,622 3,131







# HPV Prevalence in Sri Lanka Females

- In Sri Lanka, a population-based study conducted in the Gampaha district in 2008 showed an overall female HPV prevalence among clinically normal women was 3.3% (Gamage, 2017).
- Most prevalent high-risk genotypes in Sri Lankan women was 16 and 18 and their prevalence was 1.2% in 2008 (Gamage, 2017).
- Prevalence of HPV among normal cytology is 12.3% which is similar to the rates in other regions of Asia (China 15.4%; India 10.43%) (Shanaka et al., 2018)
- Study among 51 female STD attendees revealed 37 were HPV positive





# HPV Prevalence in Sri Lanka Males

- No published data on male HPV Prevalence
- Ongoing research on 'Male HPV prevalence among men of 20-70 years in community and STD attendees' (during pilot study among Male STD attendees 3/5 were positive for HPV, gene sequencing results pending)

Gunasekera et al. Infectious Agents and Cancer (2015) 10:12 DOI 10.1186/s13027-015-0007-z



#### RESEARCH ARTICLE

#### **Open Access**

A shifting paradigm in the aetiology of oral and pharyngeal cancer in Sri Lanka: a case-control study providing serologic evidence for the role of oncogenic HPV types 16 and 18

Suvanthee Kushani Gunasekera<sup>1</sup>, Kanthi Angela Perera<sup>2</sup>, Chandrika Fernando<sup>3</sup> and Preethi Vidya Udagama<sup>1\*</sup>

#### Abstract

Background: Oral and pharyngeal cancer (OPC) of multifactorial aetiology is a major health problem globally. Ranking first in all cancers, OPC poses a significant impact on the Sri Lankan male population. As Human Papillomavirus (HPV) high risk (HR) types are found to be significant risk factors for OPC globally, the current study was undertaken to examine the association between HR-HPV16 and 18 types with OPC in Sri Lanka.

Materials and methods: Serum samples of 78 OPC patients and 51 non-cancer controls were assayed for the presence of anti-HPV16 and anti-HPV18 IgG antibodies using in-house established Enzyme Linked Immunosorbent Assays (ELISAs). The association between OPC and its risk factors *i.e.* HPV, smoking, alcohol, betel quid, poor dentition, was established using Chi-square test. Logistic regression was used to calculate odds ratios (OR), adjusted for the influence of other risk factors.

**Results:** This prototype study in Sri Lanka showed a significant risk of 15 fold in developing OPC due to HPV16/18 seropositivity after removing variability due to other factors. Oncogenic HPV18 showed a higher rate of seropositivity being detected in 32% of OPC patients, and also in 2% of non-cancer control subjects. HR-HPV16 was detected in 23% of OPC patients and in 5.88% of controls. Moreover, seven OPC patients were detected with both anti-HPV16 and anti-HPV18 antibodies. According to the logistic regression models HPV18 seropositivity was associated with a 28 fold risk in developing OPC while that of HPV16 was associated with a 6 fold increase in risk for the development of OPC. A 5 fold risk of developing OPC was also pronounced among smokers while alcohol, betel and poor dentition was not significantly associated with OPC. Statistically significant differences with regard to age, gender, smoking, alcohol, betel use, poor dentition and site specificity of the tumour was not observed between HPV seropositive and seronegative OPC patients.

Conclusions: Both in-house developed ELISAs detected significant proportions of HPV seropositives within the OPC study population suggestive of HPV as a strong risk factor for oral and pharyngeal carcinogenesis in Sri Lanka.

Keywords: Sri Lanka, Oral and pharyngeal cancer, Human papillomavirus (HPV), HPV16, HPV18, Enzyme-linked Immunosorbent assay, Risk factors, Smoking

# Social & Economic Impact due to HPV related Cancers

Missing Opportunity for Preventable cancer Missing opportunity for Screening of Cervical Cancer Affected females in reproductive age group Productivity loss Cost for treatment Index patient suffering & societal suffering





COALITION to STRENGT the **HPV IMMUNIZATION** COMMUNITY





# National Cancer Registry of Sri Lanka NATIONAL CANCER CONTROL PROGRAMME

**Q** Search statistics / Type the site of cancer



FACT SHEETS



# https://dashboard.nccp.health.gov.lk

MALE FEMALE